Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack : Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial
©Dipen Patel, Yamiko Joseph Msosa, Tao Wang, Julie Williams, Omar G Mustafa, Siobhan Gee, Barbara Arroyo, Damian Larkin, Trevor Tiedt, Angus Roberts, Richard J B Dobson, Fiona Gaughran. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 05.04.2024..
BACKGROUND: Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings.
OBJECTIVE: We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust-approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting.
METHODS: This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks.
RESULTS: Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024.
CONCLUSIONS: An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/49548.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
JMIR research protocols - 13(2024) vom: 05. Apr., Seite e49548 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patel, Dipen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 26.04.2024 published: Electronic ClinicalTrials.gov: NCT04792268 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2196/49548 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370680766 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370680766 | ||
| 003 | DE-627 | ||
| 005 | 20240426234141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2196/49548 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM370680766 | ||
| 035 | |a (NLM)38578666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patel, Dipen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of an Electronic Clinical Decision Support System for the Early Recognition and Management of Dysglycemia in an Inpatient Mental Health Setting Using CogStack |b Protocol for a Pilot Hybrid Type 3 Effectiveness-Implementation Randomized Controlled Cluster Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04792268 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©Dipen Patel, Yamiko Joseph Msosa, Tao Wang, Julie Williams, Omar G Mustafa, Siobhan Gee, Barbara Arroyo, Damian Larkin, Trevor Tiedt, Angus Roberts, Richard J B Dobson, Fiona Gaughran. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 05.04.2024. | ||
| 520 | |a BACKGROUND: Severe mental illnesses (SMIs), including schizophrenia, bipolar affective disorder, and major depressive disorder, are associated with an increased risk of physical health comorbidities and premature mortality from conditions including cardiovascular disease and diabetes. Digital technologies such as electronic clinical decision support systems (eCDSSs) could play a crucial role in improving the clinician-led management of conditions such as dysglycemia (deranged blood sugar levels) and associated conditions such as diabetes in people with a diagnosis of SMI in mental health settings | ||
| 520 | |a OBJECTIVE: We have developed a real-time eCDSS using CogStack, an information retrieval and extraction platform, to automatically alert clinicians with National Health Service Trust-approved, guideline-based recommendations for dysglycemia monitoring and management in secondary mental health care. This novel system aims to improve the management of dysglycemia and associated conditions, such as diabetes, in SMI. This protocol describes a pilot study to explore the acceptability, feasibility, and evaluation of its implementation in a mental health inpatient setting | ||
| 520 | |a METHODS: This will be a pilot hybrid type 3 effectiveness-implementation randomized controlled cluster trial in inpatient mental health wards. A ward will be the unit of recruitment, where it will be randomly allocated to receive either access to the eCDSS plus usual care or usual care alone over a 4-month period. We will measure implementation outcomes, including the feasibility and acceptability of the eCDSS to clinicians, as primary outcomes, alongside secondary outcomes relating to the process of care measures such as dysglycemia screening rates. An evaluation of other implementation outcomes relating to the eCDSS will be conducted, identifying facilitators and barriers based on established implementation science frameworks | ||
| 520 | |a RESULTS: Enrollment of wards began in April 2022, after which clinical staff were recruited to take part in surveys and interviews. The intervention period of the trial began in February 2023, and subsequent data collection was completed in August 2023. Data are currently being analyzed, and results are expected to be available in June 2024 | ||
| 520 | |a CONCLUSIONS: An eCDSS can have the potential to improve clinician-led management of dysglycemia in inpatient mental health settings. If found to be feasible and acceptable, then, in combination with the results of the implementation evaluation, the system can be refined and improved to support future successful implementation. A larger and more definitive effectiveness trial should then be conducted to assess its impact on clinical outcomes and to inform scalability and application to other conditions in wider mental health care settings | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov NCT04792268; https://clinicaltrials.gov/study/NCT04792268 | ||
| 520 | |a INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/49548 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CDSS | |
| 650 | 4 | |a RCT | |
| 650 | 4 | |a blood sugar | |
| 650 | 4 | |a clinical decision support system | |
| 650 | 4 | |a decision support | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a diabetic | |
| 650 | 4 | |a dysglycemia | |
| 650 | 4 | |a electronic clinical decision support | |
| 650 | 4 | |a hyperglycemia | |
| 650 | 4 | |a hypoglycemia | |
| 650 | 4 | |a implementation | |
| 650 | 4 | |a medical informatics | |
| 650 | 4 | |a mental health | |
| 650 | 4 | |a mental healthcare | |
| 650 | 4 | |a mental illness | |
| 650 | 4 | |a metabolic health | |
| 650 | 4 | |a randomized controlled trial | |
| 700 | 1 | |a Msosa, Yamiko Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Mustafa, Omar G |e verfasserin |4 aut | |
| 700 | 1 | |a Gee, Siobhan |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Larkin, Damian |e verfasserin |4 aut | |
| 700 | 1 | |a Tiedt, Trevor |e verfasserin |4 aut | |
| 700 | 1 | |a Roberts, Angus |e verfasserin |4 aut | |
| 700 | 1 | |a Dobson, Richard J B |e verfasserin |4 aut | |
| 700 | 1 | |a Gaughran, Fiona |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JMIR research protocols |d 2012 |g 13(2024) vom: 05. Apr., Seite e49548 |w (DE-627)NLM226893626 |x 1929-0748 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g day:05 |g month:04 |g pages:e49548 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2196/49548 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |b 05 |c 04 |h e49548 | ||